PNPLA3, TM6SF2, HSD17B13, GCKR, and DGAT2 genetic variations have gained much interest in the genetic-based precision medicine of NAFLD (Table 5). This evidence concerns the gene HSD17B13 and metabolic dysfunction-associated steatotic liver disease.